HealthEquity price target raised to $134 from $130 at Jefferies

Jefferies analyst Glen Santangelo raised the firm’s price target on HealthEquity (HQY) to $134 from $130 and keeps a Buy rating on the shares. The firm maintains its positive view on HealthEquity and points to the company’s solid Q2 and accompanying guidance raise as indications of continued strong execution by management that’s translating to stock-driving earnings outperformance. The meaningful tailwind from One Big Beautiful Bill Act’s expansion of HSA eligibility is a notable positive that should boost HealthEquity’s go-forward revenue and earnings outlooks, Jefferies adds. Concerns about interest rate outlook are more than adequately reflected in the stock, the firm argues.